文献速递结核与非结核分枝杆菌

H56:IC31疫苗对药物敏感肺结核治愈后复发的影响:2b期随机对照试验

Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial.
PubMed 文献 · Lancet Infect Dis · 2025-03-05

一项在南非和坦桑尼亚开展的双盲、随机、安慰剂对照2b期试验,纳入831例完成药物敏感肺结核治疗的无HIV感染成人,评估H56:IC31疫苗减少结核复发的作用。结果显示,H56:IC31组复发结核23/400例,安慰剂组14/406例,疫苗效力为-73.8%(95%CI -246.9至9.8;p=0.10),未能降低复发风险。疫苗耐受性良好且具有免疫原性,但作者指出可能增加内源性菌株复发的风险。

要点

  • H56:IC31疫苗未能降低肺结核治愈后的复发风险,疫苗效力为-73.8%(95%CI -246.9至9.8;p=0.10)。
  • H56:IC31组复发结核23/400例,安慰剂组14/406例,其中复发和再感染分别分析均无显著差异。
  • H56:IC31在第二剂后2周显著提高H56特异性CD4 T细胞应答和IgG抗体水平,但注射部位反应更常见(40% vs 19%)。

核心结论

  • 完成肺结核治疗后接种H56:IC31疫苗未能降低复发结核的风险。
  • H56:IC31耐受性良好且具有免疫原性,但作者认为可能增加内源性菌株复发的风险。

研究设计与样本

  • 双盲、随机、安慰剂对照2b期试验,在南非5个和坦桑尼亚1个临床试验点开展。
  • 纳入18-60岁、无HIV感染、已完成药物敏感肺结核治疗超过5个月(22周)的参与者831例,随机1:1分配至H56:IC31组415例和安慰剂组416例。
  • 参与者接受两次三角肌肌内注射,间隔56天,随访至研究第421天(第二剂后1年)。
  • 主要终点为第70天(第二剂后14天)至第421天期间培养确诊的复发性肺结核。
  • 主要分析基于改良意向性治疗(mITT)人群,安全性分析纳入所有接受至少一剂疫苗或安慰剂的随机参与者。

主要发现

  • mITT分析中,H56:IC31组400例中23例发生复发结核(12例复发、8例再感染、3例不确定),安慰剂组406例中14例(6例复发、7例再感染、1例不确定)。
  • 预防复发的疫苗效力为-73.8%(95%CI -246.9至9.8;p=0.10)。
  • 预防复发的疫苗效力为-116.1%(95%CI -522.2至16.3;p=0.11),预防再感染的疫苗效力为-21.1%(95%CI -245.3至56.5;p=0.71)。
  • 第二剂后2周,H56:IC31组H56特异性CD4 T细胞(表达干扰素-γ、肿瘤坏死因子、白介素-2或白介素-17)中位百分比为0.35%(IQR 0.19至0.57),安慰剂组为0.11%(IQR 0.09至0.23),p<0.0001。
  • H56特异性IgG应答中位任意单位每mL,H56:IC31组为6.84(IQR 1.64至32.8),安慰剂组为1.94(IQR 1.05至3.86),p<0.0001。

关键数值与推荐

  • 主要终点复发结核定义:第70天至第421天期间培养确诊的复发性肺结核(同一菌株复发、不同菌株再感染或不确定)。
  • 疫苗效力通过Cox比例风险模型计算。
  • H56特异性CD4 T细胞应答和抗H56 IgG体液应答为次要免疫原性终点。

临床怎么用

  • 原文未据此给出推荐。
  • 作者结论认为,完成肺结核治疗后接种H56:IC31未能降低复发风险,疫苗耐受性良好且具有免疫原性,但可能增加内源性菌株复发的风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with tuberculosis who complete treatment remain at risk of recurrent disease. The vaccine H56:IC31 has been shown to be safe and immunogenic in phase 1 and 2 studies, but whether it can reduce the risk of tuberculosis recurrence is unknown. METHODS: In a double-blind, randomised, placebo-controlled, phase 2b trial in South Africa (five clinical trial sites) and Tanzania (one clinical trial site), we enrolled participants aged 18-60 years, without HIV, who had completed more than 5 months (22 weeks) of treatment for drug-susceptible pulmonary tuberculosis. During trial screening (≤7 days after starting treatment), two sputum samples were obtained and frozen for later comparison to recurrent isolates by whole-genome sequencing (WGS). Eligible participants were randomly assigned (1:1; block size of four) to receive two intramuscular doses in the deltoid, 56 days apart, of H56:IC31 or placebo. After the first dose of H56:IC31 or placebo, participants were followed up until study day 421 (1 year after the second dose) and checked at each visit for tuberculosis signs and symptoms. If tuberculosis was suspected, two sputum samples were obtained: one sample was tested by automated molecular test (Xpert MTB/RIF Ultra) and sent for liquid culture; and the other sample was stored frozen for later analysis by whole-genome sequencing (WGS). At the last visit (day 421), two sputum samples were obtained from all sputum-productive participants, regardless of symptoms, to detect cases of asymptomatic tuberculosis. The primary endpoint was culture-confirmed recurrent pulmonary tuberculosis (due to relapse with the same strain, reinfection by a different strain, or indeterminate) occuring during the period starting at day 70 (14 days after the second dose) and ending on day 421 (1 year after the second dose). Vaccine efficacy against recurrent tuberculosis was derived from Cox proportional hazards models. Secondary endpoints included vaccine efficacy to prevent tuberculosis relapse or reinfection independently, as differentiated by WGS, and safety and immunogenicity outcomes (H56-specific CD4 T-cell responses and humoral anti-H56 IgG responses). Primary analysis of vaccine efficacy was based on modified intention-to-treat (mITT), in all randomly assigned participants except those with tuberculosis disease recurrence or who withdrew before day 70 (or 14 days after the second dose for those who received both doses). Safety was assessed in all randomly assigned participants who received at least one dose of vaccine or placebo. The trial was registered with ClinicalTrials.gov, NCT03512249, and is complete. FINDINGS: 831 participants (mean age 34·7 years [SD 11·1]; 229 [28%] female and 602 [72%] male; 549 [66%] Black) were enrolled from Jan 31, 2019, to Jan 20, 2022; 415 participants were randomly assigned to receive H56:IC31 and 416 to receive placebo. Follow-up was completed by March 20, 2023 (mean follow-up duration 410·1 days [SD 82·8]). In the primary mITT analysis, recurrent tuberculosis occurred in 23 of 400 participants in the H56:IC31 group (12 relapses, eight reinfections, and three indeterminate); and in 14 of 406 in the placebo group (six relapses, seven reinfections, and one indeterminate). Vaccine efficacy for prevention of recurrence was -73·8% (95% CI -246·9 to 9·8; p=0·10). Vaccine efficacy for prevention of relapse was -116·1% (-522·2 to 16·3; p=0·11) and for prevention of reinfection was -21·1% (-245·3 to 56·5; p=0·71). 2 weeks after the planned second dose, H56:IC31 had significantly increased the frequencies of H56-specific CD4 T cells expressing interferon-γ, tumour necrosis factor, interleukin (IL)-2, or IL-17 in vaccinees (median percentage of CD4 T cells, 0·35% [IQR 0·19 to 0·57]) compared with placebo (0·11% [0·09 to 0·23]; p<0·0001). H56-specific IgG responses were significantly higher in H56:IC31 recipients (median arbitrary units per mL, 6·84 [IQR 1·64 to 32·8]) than in placebo recipients (1·94 [1·05 to 3·86]; p<0·0001). A greater proportion of H56:IC31 recipients had mild-to-moderate injection site reactions than placebo recipients (165 [40%] of 415 vs 78 [19%] of 416). No treatment-related serious adverse events were reported. Two participants who received H56:IC31 and six who received placebo died. INTERPRETATION: Vaccination with H56:IC31 at treatment completion for pulmonary tuberculosis did not reduce the risk of recurrent disease. H56:IC31 was well tolerated and immunogenic but might have increased the risk of relapses by endogenous strains. FUNDING: The European and Developing Countries Clinical Trials Partnership (EDCTP2) supported by the EU (grant number RIA2016V-1631, POR TB consortium). Additional funding to support completion of the trial was provided by the Statens Serum Institut, Aurum Institute, and the South African Tuberculosis Vaccine Initiative.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Borges ÁH, Russell M, Tait D, et al. Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Infect Dis. 2025. PMID: 40056922. doi:10.1016/S1473-3099(24)00814-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。